Cl Inical Observation Of Deng Jianxin Prescription Improve The Quality Of Life In Patients With Coronary Heart Disease After PCI

Objective:Preliminary evaluation of the early efficacy of Deng Jianxin Prescription for coronary heart disease patients with syndrome with Qi deficiency and stasis-phlegm syndrome after PCI, including the effect of the clinical symptoms, quality of life impact and safety.Methods:60 consecutive cases of coronary heart disease after PCI with qi deficiency and stasis-phlegm syndrome Heart center of Guangdong Province Chinese Medical Hospital were divided into the control group and the test group randomly. The control group were treated with Conventional Western standard treatment, and the test group were treated with Conventional Western standard treatment and Deng Jianxin Prescription, for 4 weeks. Taking early efficacy evaluation and analyzing safety of Deng Jianxin Prescription after 4 weeks’ treatment course. Efficacy evaluation indexes including the traditional Chinese medicine syndromes scores, angina classification and quality of life scale, the scale of quality of life for the short-form-36 health survey(SF-36), Seattle Angina Questionnaire(SAQ); safety indicators for adverse reactions and laboratory values.Results:After 4 weeks’ therapy, the TCM syndromes scores were statistical significantly lower in trial group(P<0.05) than control group. Total effective rate in trial group was 77.7% while it’s 43.3% in control group. And there was no statistical significance between two groups on improvement of angina symptoms.In respect of quality of life evaluation, trial group had higher integral in all of the dimensionality of SF-36 with statistical significant differences in physical function, role-physical, reported health transition and social function (P<0.05). Trial group had significant higher scores in dimensionality of disease perception, anginal frequency, treatment satisfaction and physical limitation(P<0.05) in SAQ. But there was no statistical significance between two groups on anginal stability (P>0.05)No obvious and serious adverse events were occured in two groups.Conclusion:Deng Jianxin Prescription can improve the early clinical symptoms and the quality of life of coronary heart disease patients after PCI with qi deficiency and stasis-phlegm syndrome, and is safe.